Into the limelight: TPA for critically ill Covid-19 patients
- PMID: 35941887
- PMCID: PMC9347851
- DOI: 10.1002/jha2.429
Into the limelight: TPA for critically ill Covid-19 patients
References
-
- Zhang Z, Zhai Z, Liang L, Liu F, Yang Y, Wang C. Lower dosage of recombinant tissue‐type plasminogen activator (rt‐PA) in the treatment of acute pulmonary embolism: a systematic review and meta‐analysis. Thromb Res. 2014;133(3):357–63. - PubMed
-
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G‐J, Harjola V‐P, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(4):543–603. - PubMed
-
- Tisdale JE, Colucci RD, Ujhelyi MR, Kluger J, Fieldman A, Chow MSS. Evaluation and comparison of the adverse effects of streptokinase and alteplase. Pharmacother J Hum Pharmacol Drug Ther. 1992;12(6):440–4. - PubMed
-
- Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients. J Thromb Haemost. 2005;3(4):692–4. - PubMed
Publication types
LinkOut - more resources
Full Text Sources